Literature DB >> 2476969

[Chemotherapy with Cisplatin-Phosphatidyl-choline-Lipiodol (CPL) suspension in unresectable hepatocellular carcinoma].

Y Aoki1, K Hirai, K Yamashita, H Noguchi, T Sakai, Y Majima, K Tanikawa, H Inoue, Y Okano, T Hitoshi.   

Abstract

Twenty-seven patients with unresectable hepatocellular carcinoma (HCC) were treated with Cisplatin-Phosphatidyl-choline-Lipiodol (CPL) suspension. PR was obtained in two of ten cases (20%) by one shot therapy. AFP decreased in 9 of 10 patients by one shot therapy with a 62.1% rate of decrease. In all of 13 patients by TAE, AFP decreased and the rate of decrease was 64.8%. The concentration of CDDP in the peripheral venous blood was lower and continued longer than that of CDDP on the market. Nausea, vomiting and fever were noted in most cases as adverse effects, but they were slight. These results suggest that CPL agents were very chemotherapeutic for unresectable HCC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476969

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Segmental stenosis of ureter: a late complication of intra-arterial chemotherapy for bladder cancer.

Authors:  P K Saha; K Taniguchi; N Maekawa; H Suzu; S Yamashita; H Kanetake; Y Saito
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma.

Authors:  Yanmei Cui; Chuyong Lin; Zhiqiang Wu; Aibin Liu; Xin Zhang; Jinrong Zhu; Geyan Wu; Jueheng Wu; Mengfeng Li; Jun Li; Libing Song
Journal:  Oncotarget       Date:  2014-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.